期刊
BIOMEDICINES
卷 10, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10020459
关键词
GAHT; testosterone; methylation; ESR2; gender incongruence
资金
- Italian Ministry of University and Research [MIUR-PRIN 2017FC4BS9]
Virilization of AFAB individuals through testosterone therapy can result in phenotypic changes, although inter-individual differences in timing and acquisition of characteristics are commonly observed. The study investigated the relationship between CpG methylation profiles of ESR2 and H19 promoters and their influence on phenotypic modifications in AFAB individuals undergoing testosterone therapy. Results showed a significant increase in methylation of the ESR2 promoter but not the H19 promoter after 6 and 12 months of treatment. Epigenetic changes appeared to be regulated and associated with patient age and testosterone levels. The study suggests that epigenetic regulation may play a role in phenotypical changes after testosterone treatment.
Virilization of gender-incongruent subjects to whom were assigned the female gender at birth (AFAB) is achieved through testosterone administration. Inter-individual differences in the timing and acquisition of phenotypic characteristics, even if the same hormone preparations and regimens are used, are frequently observed. Polymorphisms of sex hormone receptors and methylation of their gene promoters, as well of several imprinted genes as H19, may underlie the differential response to treatment. Thus, the aim of this study was to examine the possible relationship between the CpG methylation profile of the estrogen receptor 2 gene (ESR2) and H19 promoters and their influence on phenotype modifications in a cohort of AFAB people at baseline (T0) and after 6 mo (T6) and 12 mo (T12) of testosterone therapy (testosterone enanthate, 250 mg i.m. every 28 d). A total of 13 AFAB subjects (mean age 29.3 +/- 12.6) were recruited. The percentage of methylation of the ESR2 promoter significantly increased at T6 (adj. p = 0.001) and T12 (adj. p = 0.05), while no difference was detected for H19 (p = 0.237). Methylation levels were not associated with androgen receptor (AR)/estrogen receptor beta (ER beta) polymorphisms nor hormone levels at baseline and after six months of treatment. On the other hand, total testosterone level and patient age resulted in being significantly associated with ESR2 methylation after twelve months of treatment. Finally, the difference in ESR2 promoter methylation between T6 and baseline was significantly associated with the number of CA repeats of the ER beta receptor, adjusted vs. all considered variables (R-2 = 0.62, adj. R-2 = 0.35). No associations were found with CAG repeats of the AR, age, and estradiol and testosterone levels. Despite the small sample size, we can hypothesize that treatment with exogenous testosterone can modify the ESR2 methylation pattern. Our data also indicated that epigenetic changes may be regulated, suggesting that the modulation of estrogen signaling is relevant shortly after the beginning of the treatment up to T6, with no further significant modification at T12. Furthermore, estrogen receptor methylation appears to be associated with the age of the subjects and exogenous testosterone administration, representing a marker of androgenic treatment. Nonetheless, it will be necessary to increase the number of subjects to evaluate how epigenetic regulation might play a relevant role in the modulation of phenotypical changes after testosterone treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据